This is a single-center, prospective, controlled, double-blind, randomized study. A total of
50 renal transplant recipients diagnosed with post-transplantation diabetes mellitus (PTDM)
will be included more than 1 year after transplantation and randomized 1:1 to empagliflozin
(Jardiance®) 10 mg or placebo once daily for 24 weeks. Patients with estimated glomerular
filtration rate below 30 mL/min will be excluded. Oral glucose tolerance test, 72h continuous
glucose monitoring (iPro™2), measurement of arterial stiffness, body composition (including
visceral fat), 24h blood pressure and 24h urinary glucose excretion will be performed at
baseline and after 24 weeks in addition to standard safety measurements. Two safety visits
will be performed at week 8 and 16. All concomitant medication, diet and exercise will be
kept stable during the study period. The objective of the present study is to answer whether
empagliflozin safely and effectively improves glucose metabolism together with weight loss in
renal transplant recipients with PTDM.